Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03720522

The Bern Heart and Brain Interaction Study - Interaction Between Brain and Heart in Acute Ischemic Stroke

Acute ischemic stroke is caused by blockage of blood vessels in the brain. Blood vessels can be obstructed by several different mechanisms and identification of this cause is essential to minimize the risk of recurrence.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–86 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bern University Hospital - Inselspital

Bern, Canton of Bern, 3010, Switzerland

Location status: Recruiting

Location contact

Simon Jung, PD Dr. med.

CONTACT

[email protected]

Simon Jung, PD Dr. med.

PRINCIPAL_INVESTIGATOR

About this study

Acute ischemic stroke is caused by blockage of blood vessels in the brain. This obstruction may be due to the presence of a blood clot, which prevents the passage of blood. Because the brain is under-irrigated, nerve cells lack oxygen and nutrients and can die, which can lead to brain function disorder.

Blood vessels can be obstructed by several different mechanisms and identification of this cause is essential to minimize the risk of recurrence. For instance, it may be a blood clot that originally formed in the heart, which breaks off and is carried away by the blood flow into an artery of the brain, which it blocks. The formation of such a clot can be caused by a heart attack, as a heart attack causes reduced mobility of certain parts of the heart, which greatly increases the risk of clot formation. At the same time, a stroke can also induce cardiac changes, for example because of the production of stress hormones secreted during a stroke. These cardiac changes due to stress hormones can greatly look like cardiac changes caused by a heart attack.

As a consequence, when a stroke is caused by a heart attack, it is often very difficult to correctly diagnose the heart attack and therefore treat patients properly. Indeed, symptoms and effects of a stroke and a heart attack may be similar, although these are two completely different medical problems. In order to gain additional knowledge, the investigators aim with this study to make the diagnosis of a heart attack more precise in patients suffering from a stroke.

Hypothesis, primary and secondary objectives:

The investigators postulate that the combination of laboratory, clinical, radiological, echocardiographic and electrophysiological assessments in a predictive score can distinguish myocardial infarction (MI) and neurogenic stunned myocardium (NSM) in stroke patients (MI and NSM defined by cardiac MRI and coronary angiography).

Primary objectives: The primary objective is to assess the prevalence of MI and NSM, with or without wall motion abnormalities, in stroke patients.

Secondary objectives: Secondary objectives aim to develop a predictive score out of laboratory, clinical, radiological (brain MRI), echocardiographic and electrophysiological parameters to identify stroke patients with MI and to distinguish them from patients with NSM.

The project will add important information to the pathogenesis of NSM, the importance of MI in stroke and the clinically relevant question of the management of stroke patients with hsTnT elevations. On one hand, the project offers the chance to improve the identification of patients with relevant coronary sclerosis. The investigators postulate that most of these patients are not identified by current practice. An early identification of these patients is necessary for early treatment and prevention of cardiac events.

On the other hand, the project offers the chance to improve the identification of patients with NSM and to deliver information on clinical relevance of NSM including arrhythmias and wall motion abnormalities. Given the negative association of NSM with outcome after stroke, the identification of NSM patients is the necessary condition for a treatment trial. Beta-blockers could for instance be beneficial for stroke patients with NSM and such a project could have far-reaching consequences on the management of many acute stroke patients in the near future.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent as documented by signature.
  • Age: ≥ 18 and < 86 years.
  • Acute ischemic stroke with symptom onset within 12 hours before admission to hospital.
  • Diagnosis of acute ischemic stroke with MRI with diffusion restriction as seen on diffusion weighted imaging.

Exclusion criteria

  • Pregnancy. A negative pregnancy test upon admission is required for all women with child-bearing potential.
  • Standard contraindication for performing MRI.
  • Severe renal failure (GFR <40).

Treatment and study plan

Short cardiovascular MRI (CMR)

Procedure

A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).

Adenosine-perfusion cardiovascular MRI (CMR)

Procedure

An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.

Blood draw

Procedure

The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis

Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.

Urine (collection over 24h)

Procedure

The following study-specific parameters will be tested: catecholamines.

Time points for collection: at 24h, 72h, and 3 months

Primary outcomes

  1. Prevalence of neurogenic stunned myocardium (NSM) in ischemic stroke patients with elevated hsTnT (≥ 0.015 mg/L)

    Time frame: 48 hours

  2. Prevalence of neurogenic stunned myocardium (NSM) in ischemic stroke patients with elevated hsTnT (≥ 0.015 mg/L)

    Time frame: 3 months

Secondary outcomes

  1. Prevalence of sub(acute) and chronic myocardial infarction in stroke patients with and without elevated hsTnT (≥ 0.015 mg/L)

    Time frame: At baseline, 24 hours, 48 hours, 3 months

  2. Positive and negative predictive value of the developed predictive score to detect myocardial infarction and neurogenic stunned myocardium compared to CMR and coronary angiography

    Time frame: At baseline, 24 hours, 48 hours, 72 hours, 3 months

  3. Influence of neurogenic stunned myocardium on neurological outcome (as measured by modified Rankin Scale)

    Time frame: At baseline, 24 hours, 3 months

    The modified Rankin Scale (mRS) measures the degree of disability or dependence (minimum: 0 [normal]; maximum: 6 [death]). Favorable outcome is defined as a mRS score of 0 to 4, poor outcome as a mRS score of 5 or 6.

  4. Influence of neurogenic stunned myocardium on brain infarct size (as measured by brain MRI)

    Time frame: At baseline, 24 hours, 3 months

Study contacts

Contact information is provided by the study sponsor or research team.

Marianne Kormann

CONTACT

[email protected]

+41 31 632 06 48

Simon Jung, PD Dr. med.

CONTACT

[email protected]

+41 31 632 79 56

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Registry information

Acronym: BEHABIS

Important dates

Study start
2018
Primary completion
2025
Study completion
2026
First posted
Oct 25, 2018
Registry last updated
Nov 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.